×

Neville Registrars is pleased to announce that it will be exhibiting at The ICSA Annual Conference 2019 to be held on the 9th & 10th July (8.30am – 5.30pm) at the ExceL Conference Centre, London.

Please find us at Stand 31 where we will be delighted to discuss your Company's requirements and outline the numerous services/products we can offer.

Close

×

RNS Number : 4280E

ValiRx PLC

04 July 2019

 

 

 

 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

 

UPDATE RE VAL301

FOR THE TREATMENT OF ENDOMETRIOSIS

 

"ValiRx progresses VAL301 Clinical Development Plan"

 

London, UK., 04 July 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to announce that the Company's clinical team has signed an agreement to work with Aptus Clinical Ltd ("Aptus"), the UK based, clinical Contract Research Organisation ("CRO"), to effectuate a clinical development plan for VAL301 incorporating a Phase I/II study design concept in Endometriosis.

 

Aptus will be working with ValiRx on regulatory, technical and scientific areas, in order to bring VAL301 nearer to the clinic.

 

Endometriosis is a benign, oestrogen -dependent chronic condition, characterised by endometrial tissue growth outside of the uterus.  Symptoms including heavy painful periods, pain with intercourse and infertility are often severe and are associated with a decreased quality of life for young women. The condition affects an estimated 1 in 10 women during their reproductive years, equating to approximately 176 million women worldwide*, posing a high economic burden.

 

VAL301 is derived from the same active pharmaceutical ingredient as VAL201, which is currently in a Phase I/II clinical trial where the compound has demonstrated safety and has been well tolerated. These positive results will be used to strengthen the clinical application of the development programme.  Pre-clinical studies indicate that treatment with VAL301 should not affect bone density or fertility, two of the major problems associated with current medical treatments for endometriosis. ValiRx intends to develop VAL301 as a non-invasive, effective and better tolerated treatment for this debilitating condition.

*Source: https://www.ncbi.nlm.nih.gov/pubmed/30026507

 

Dr Satu Vainikka, CEO of ValiRx, commented: "Our agreement with Aptus represents an important stage in preparing the VAL301 compound for clinical study. I look forward to VAL301's future development and its potential to benefit women who suffer from this extremely painful condition".

 

Dr Steve McConchie, Co-founder & CEO of Aptus, added: "We are delighted to have been selected by ValiRx to work on the development plan options for VAL301 in endometriosis. We look forward to exploring some innovative opportunities with the team in order to optimise the programme delivery timelines and progress this important potential treatment rapidly to patients".

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

 

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Novum Securities Limited Colin Rowbury	Tel: +44 (0) 20 7399 9400

 

Notes for Editors

 

About Aptus

Aptus is a UK based, clinical CRO with particular expertise in oncology, rare diseases and advanced (cell and gene) therapies. The company provides design, set-up, management and monitoring of early phase clinical trials. In addition, it supports clients with a range of specialist services that include quality management frameworks, clinical governance support and a number of digital solutions that facilitate data storage, analysis and visualisations.

 

Aptus are partners in iMATCH (innovate Manchester Advanced Therapy Centre Hub), a consortium of experts from industry, academia and the NHS, funded by Innovate UK. The iMATCH objective is to accelerate the safe and effective delivery of advanced therapies to increasing numbers of patients within the NHS.  Aptus are also preferred suppliers to the Cell and Gene Therapy Catapult.

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College. 

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCBRGDRXSGBGCX

Close

×

RNS Number : 3368E

Midatech Pharma PLC

03 July 2019

 

3  July 2019

Midatech Pharma PLC

 

("Midatech" or the "Company")

 

 

MTX110 Update

 

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce an update on its key MTX110 programme.

 

MTX110 is designed for the treatment of childhood brain cancers such as Diffuse Intrinsic Pontine Glioma ("DIPG"), an ultra-rare highly aggressive and inoperable tumour located in the brain stem, that is universally fatal with an average life expectancy of 7 to 9 months.  Midatech is also evaluating MXT110 for the treatment of Glioblastoma Multiforme ("GBM"), which is a fast-growing form of brain cancer in adults.

 

The initial MTX110 study (PNOCO15) in DIPG patients, began in May 2018 and is a combined Phase I (safety) and Phase II (efficacy) programme.  Phase I is a dose escalating component originally designed with five dose levels; however, since MTX110 has been well tolerated in the patients treated to date, a further two higher dose levels have been added to the study. This Phase I component is scheduled to complete in Q3 2019.

 

Based on the Phase I progress to date, the Recommended Phase II Dose ("RP2D") has preliminary been set at the upper dosage level achieved in this Phase I component.  A further small cohort of three patients will now be treated to complete the "3+3 design", the traditional standard dose escalation schedule in the development of cancer therapeutics, and to confirm this RP2D dose, bringing the total number of patients treated at the final RP2D to five. We expect these patients will join the Phase II efficacy component, which is scheduled to start during Q3/4 2019, following confirmation from the US Food and Drug Administration.

 

Dr Sabine Mueller, Principal Investigator for the study said: "Midatech's MTX110 has shown promise as one of the most potent compounds against DIPG brain tumour cells in laboratory experiments.  In this first in human study of MTX110 we are encouraged by the excellent safety profile so far and look forward to completing the safety evaluation and commencing the efficacy assessment of the drug later this year."

 

Midatech's Chief Executive Officer, Dr Craig Cook, said: "We are delighted to be able to give this update on how the MTX110 programme is progressing. The patients have reacted very well from a safety perspective to MTX110 to date and we hope to advance to the Phase II component later this year and further evaluate MTX110 as a very promising therapy for DIPG, for which there are no effective treatments. We look forward to providing further updates as the development programme progresses."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

 

For more information, please contact:

 

Midatech Pharma PLC

Dr Craig Cook, CEO

Tel: +44 (0)1235 888300

www.midatechpharma.com

 

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance) 

James Stearns (Corporate Broking)

Tel: +44 (0)20 7886 2500

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring / Heather Armstrong

Tel: +44 (0)20 3934 6630

Email: [email protected]

 

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: +1 339 970 2843

Email: [email protected]

 

 

About Midatech Pharma PLC

 

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body.  The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.

 

The Company has developed three in house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 

·    Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

·    MidaSolve™ platform: an innovative nano-technology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

·    MidaCore™ platform: a leading edge nano-technology used for targeting medications to sites of disease.

 

By improving biodelivery and biodistribution of approved existing molecules, Midatech's unique R&D makes medicine better, lowers technical risks, accelerates regulatory approval and route to market, and provides newly patentable products.  The platform nature of the technologies allows the potential for multiple drug assets rather than being reliant on a single or limited programmes.

 

Midatech's headquarters and R&D facility is in Cardiff, UK, and manufacturing operation in Bilbao, Spain.  For more information please visit www.midatechpharma.com

 

Forward-Looking Statements

 

Certain statements in this announcement may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such forward-looking statements include, but are not limited to, statements expressed or implied regarding our plans, goals, and milestones, our ability to successfully test, manufacture, produce or commercialise products for conditions using our drug delivery platforms, the ability for products in development, including MTX110, to achieve positive clinical results, the ability to meet or achieve timelines associated with pre-clinical studies, clinical trials or regulatory submissions and the associated costs of such studies, trials or submissions, and other economic, business and/or competitive factors. The risks included are not exhaustive. Any forward-looking statements are based on currently available competitive, financial and economic data together with management's views and assumptions regarding future events and business performance as of the time the statements are made and are subject to risks and uncertainties. We wish to caution you that there are some known and unknown factors that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements.

 

Reference should be made to those documents that we shall file from time to time or announcements that may be made by the Company in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning the Company are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, we do not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDLIFLTDRIVIIA

Close

×

RNS Number : 5668D

Crimson Tide PLC

27 June 2019

 

Crimson Tide plc

 

("Crimson Tide" or "the Company")

 

Contract Wins and New Partnerships

 

Crimson Tide is pleased to report a number of contract wins for its mpro5 platform as well as new partnership agreements.

In the Middle East, the Company has won an mpro5 contract through their newly appointed partner Dcode.   The contract is for one of the leading waste management companies operating in the region and provides a solid platform to build out a stronger presence in 2020.  It is expected that the deployment will extend to several hundred users during the course of the next 12 months.

Crimson Tide is in the process of finalising a contract with Compass Group in Denmark. This promises to be the first of several countries rolling out mpro5 for Compass Group, where the Company aims to expand its footprint across the group. Compass currently operates in 45 countries.

On the subject of Internet of Things (IoT), the Company is excited by its partnership with KoolZone, experts in IoT monitoring across a number of sectors. Integrating KoolZone's extensive suite of sensors into mpro5 strengthens and broadens the unique offering in the IoT market of directing workflow as a result of sensor readings. KoolZone have expanded the catalogue of sensors available within mpro5 and their expertise enhances Crimson Tide's ability to match the best sensors with each mpro5 IoT opportunity.

Crimson Tide has won a contract for an innovative pilot in Ireland with a local county council utilising both mpro5's IoT and mobile workflow features.  This appears to be one of the first of its kind in this market sector and whilst it is too early to estimate the longer-term impact, there is a significant need to automate much of the paperwork and processes in this sector.

A new contract has been signed with Interserve for three years. The group has been a loyal customer for many years and uses mpro5 to deliver industrial cleaning and security auditing across a multitude of large customers such as the BBC, Sainsbury's and the NHS.

Barrie Whipp, Executive Chairman, commented:

 

"The sales strategy implemented at the end of 2018 is bearing fruit in what readers will understand is a market with uncertainties. Our ability to grow our long term contracted revenues demonstrates how robust our model is. I reiterate my confidence in the sales growth strategy that commenced in 2018"

 

Enquiries:

 

Crimson Tide plc                           Barrie Whipp / Luke Jeffrey	01892 542444
Arden Partners John Llewellyn-Lloyd / Dan Gee-Summons	020 7614 5900

For further information on Crimson Tide plc, see the website at: www.crimsontide.co.uk/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTFFMRTMBTTBFL

Close

×

RNS Number : 2399D

Bidstack Group PLC

24 June 2019

 

RNS Reach

24 June 2019

Bidstack Group PLC ("Bidstack" or "the Company")

Results of Independent Study by Lumen Research

Bidstack Group plc (AIM: BIDS.L), the native in-game advertising group, is pleased to announce the results of an independent study commissioned by Bidstack which used eye tracking technology to measure and predict visual engagement with advertisements across several of its gaming titles.

The study was carried out by Lumen Research Limited, an attention technology company which has developed eye tracking software. Eye tracking offers a scientific and objective measure of the reality of attention. Instead of asking questions about what people thought they saw, Lumen's technology monitors what they actually looked at.

The study was designed to discover how much attention Bidstack adverts receive during a typical gamer session, to identify the kind of in-game ads that perform best and to compare native in-game advertising to digital browsing norms.

The results of the study were extremely positive for Bidstack. Bidstack's ads outperformed online browsing norms across all the titles tested, in some cases by more than double. When gamers who play every day interacted with Bidstack's ads they performed well above industry standards – demonstrating their value as an audience.

James Draper, CEO of Bidstack, commented, "We are thrilled with the outcome of this study which gives us independent proof that our product works in a demonstrable way for our clients.

"The results indicate that our advertising inventory outperforms display advertising in terms of brand recall, when exposed to a gaming audience which is an incredible result for the new industry and vertical we are building. "We are working to create a net new advertising category and, in doing so, media planners across the world will begin to recognise native in-game advertising alongside existing categories such as out of home or online display advertising.

"Bidstack is working through a number of independent viewability, brand safety and verification studies – to showcase the impact of our inventory.

"This study has helped us to understand where the premium placements are in-game and to refine our creative guidelines by game and environment, for example football vs racing games. This continued research is helping us define viewability in our various gaming environments and to evolve our programmatic pricing structure.

The positive results have come at a good time for the business and represent another step forward in our development along with our recent award of a DTSG Brand Safety Seal."

Mike Follett Managing Director at Lumen Research, said: "We were really excited about the opportunity to work with Bidstack as gaming is a growing media channel with relatively little existing research. As attention specialists, we worked closely with the Bidstack team to understand the nuances of their inventory and grasp how their audience interact with their in-game ads.

"Our bespoke approach involved utilising our proprietary eye tracking software across a diverse demographic sample, with an even gender split and an 18-65+ age range.

"Our objective was to measure in-game attention, identify the ads that performed best and benchmark the results against digital browsing norms. The findings showed consistent engagement rates from participants and that, crucially, for "every day gamers" Bidstack's ads outperformed online browsing norms in all of their titles."

~ENDS~

Contacts

Bidstack Group PLC

James Draper, CEO                                                                             +44 (0) 7850 341 885

SPARK Advisory Partners Limited (Nomad)

Mark Brady/Neil Baldwin/James Keeshan                                           +44 (0) 203 368 3550

Peterhouse Capital Limited (Broker)

Eran Zucker/Lucy Williams/Duncan Vasey                                         +44 (0) 20 7409 0930

Notes to editors

Bidstack

Bidstack is an advertising technology company which provides dynamic, targeted and automated native in-game advertising for the global video games industry across multiple platforms. Its proprietary API technology is capable of inserting adverts into natural advertising space within video games across multiple video games platforms (mobile, PC and console).

Bidstack's customers are games publishers and developers and advertising agencies, brands and programmatic advertising platforms. Bidstack contracts exclusive access to the native in-game advertising space within video games from their developers or publishers and sells that advertising space either direct to specific brands and their agencies or through programmatic advertising platforms.

DTSG

The Digital Trading Standards Group (DTSG) was set up in 2012 to bring the industry together to propose guidelines aimed at significantly reducing the risk of misplacement of advertising across the digital trading ecosystem.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

NRALLFVSRDISFIA

Close

×

RNS Number : 8083C

ValiRx PLC

20 June 2019

 

 

 

VALIRX PLC

("ValiRx" or the "Company")

 

CLINICAL UPDATE

 

 

MHRA and REC approve a major update to the trial of VAL201 including the appointment of a Principle Investigator to the clinical team

 

Results from the first clinical trial of VAL201 are being prepared for an independent evaluation following the completion of the current patient group.

 

London, UK, 20 June 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides an update on its therapeutic drugs, VAL201 and its current clinical status.

 

VAL201 clinical trial

ValiRx is pleased to announce that based on its clinical results, a substantial amendment to the clinical trial protocol has received regulatory approval from the Medicines and Healthcare products Regulatory Agency ("MHRA") and the Research ethics committee (REC)

 

Following approval of the substantial amendment, an authoritative prostate cancer specialist, Dr Mark Linch has been appointed as Principal Investigator to the clinical trial team at University College London Hospital ("UCLH").  Dr Linch is an Honorary Senior Lecturer at University College London (UCL) Cancer Institute, where he leads the Uro-oncology Biology Group, and he is also a Consultant Medical Oncologist specialising in the treatment of prostate and bladder cancer at UCLH.  Dr Rebecca Kristeleit continues with the study as Chief Investigator.

 

To date, the results generated by the trial, aided by sizable analytical methods developments, have shown that safe toxicological limits can be significantly elevated and applied to much higher levels in humans, than was suggested by the pre-clinical studies. The approval given to relax the restrictions previously applied to the trial, mean that a more effective use of VAL201 can be achieved, with respect to concentration and timing and regarding increased flexibility in the administration of the drug.

 

Additionally, the amendment relating to dosing strategies means that, in light of accumulated clinical data, the Company is able to develop further protocols. These will be designed to evaluate a range of defined therapeutic approaches that are to be tested against each other, to determine the most effective approach, in terms of disease management, cost effectiveness and patient welfare, in further clinical trials. These protocols will be the precursor to seeking approval to conduct trials aimed at gaining sufficient data to secure partnering and then Market Approval Application.

 

ValiRx reports that the trial thus far has met all the primary and secondary endpoints. The safety and tolerability results continue to be acceptable and further evidence of the compound's positive effect in reducing the progress of prostate cancer has been witnessed. The data from the trial is currently being collated for examination by independent third party experts. The approval of the amendment further validates the Company's clinical development throughout VAL201's First-in-Human Trial. Further information connected to the data and the results and findings from the trial will form the basis of a report outlining the compound's clinical profile and behaviour, which will be published in due course.

 

Dr George Morris, COO of ValiRx, commented:

"This substantial amendment has taken a lot of effort from the whole team both internal and by all our service providers to achieve. I am profoundly grateful to them all. The most gratifying thing is that our original pre-clinical experimental data has held up well and been vindicated throughout the whole of this first-in-human trial. Now, as the trial is delivering an extensive and positive output, it is also providing practical information back to the trialling of VAL201, so that the next stage of clinical development, in which we will endeavour to show how effective the compound actually is, can be entered into with confidence and support from all those involved."

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

*** ENDS ***

 

For more information, please contact:

ValiRx plc	Tel: +44 (0) 20 3008 4416 www.valirx.com
Dr Satu Vainikka, Chief Executive	Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.	Tel: +44 (0) 7879 458 364 [email protected]
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	Tel: +44 (0) 20 7213 0880
Novum Securities Limited (Broker) Colin Rowbury	Tel: +44 (0) 20 7399 9400

 

 

Notes for Editors

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

UPDUKUVRKVANAAR

Close

×

Neville Registrars is delighted to welcome Libero Pharma Limited as the newest addition to its list of client companies.

 

Close

×

Neville Registrars is delighted to welcome Innovative Power Generation Limited as the newest addition to its list of client companies.

 

Close

×

RNS Number : 4405B

Microsaic Systems plc

07 June 2019

 

7 June 2019

Microsaic Systems plc

 

("Microsaic" or the "Company")

 

Distribution Agreement with CM Corporation Ltd.

 

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that it has signed a distribution agreement with CM Corporation Ltd ("CM-C") for the exclusive distribution of the Microsaic 4500 MiD® MS detector in South Korea.

 

Established in 2000, CM-C is a specialist distributor of life science and analytical equipment, covering a wide range of markets in South Korea, including natural products, organic synthesis, pharmaceuticals, foods and environmental.

 

Glenn Tracey, CEO of Microsaic, commented, "We are very pleased to partner with CM-C in South Korea. In particular, the team at CM-C has the in-depth technical expertise in two key areas of interest for us: reaction monitoring and thin layer chromatography.

 

"Online MS can enable rapid chemical quantification (<1 min analysis duration), for desired compounds and intermediates. MS can provide a greater degree of structural information and product composition, compared with optical spectroscopy, all in real-time due to its short method times. Consequently, MS is becoming the analytical technique of choice for optimising an automated flow reactor, as the technique determines steady state and then calculates a product yield with minimal data manipulation. Furthermore, Microsaic's MS technology is specifically designed for point of need applications.

 

"Estimates of the global market size for the reaction monitoring equipment market are in the region of $1.5 billion by 2022, with leading annual growth rates in Asia Pacific.

 

"We work exclusively with local partners, knowledgeable in separation and MS technologies. Our strategy continues to be focused on business development in all key geographies."

 

Mo Hoyule, Managing Director of CM-C, added: "We are delighted to be distributing Microsaic's technology, alongside globally recognised brands such as CAMAG and ThalesNano. This will enable us to offer our customers in South Korea a total solution in some very exciting growth areas in on-line chemical monitoring."

 

This distribution agreement is the tenth partner signing for Microsaic, further extending its geographic reach.

 

Enquiries:
Microsaic Systems plc Glenn Tracey, CEO Bevan Metcalf, FD	+44 (0) 1483 751 577
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson (Corporate Finance) Tom Salvesen (Corporate Broking)	+44 (0)20 7496 3000
IFC Advisory Ltd (Financial PR) Graham Herring Heather Armstrong Florence Chandler	+44 (0)20 3934 6630

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

Microsaic's core product, the 4500 MiD®, is a robust and compact MS system, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs. For more information, please go to www.microsaic.com.  

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

CNTLLFVERSIRIIA

Close

×

RNS Number : 5633B

EVR Holdings PLC

07 June 2019

 

EVR Holdings plc

("EVR" or the "Company")

Strategic Partnership with John Gore Organization for Theatrical Content

New Equity Issue at 4.5p per share to raise £5.0 million

Issue of Option to potentially raise a further $10.0 million valuing the Company at £220m

EVR Holdings plc (AIM:EVRH), the leading creator of virtual reality entertainment content and operator of the MelodyVR platform, is pleased to announce that it has entered into a binding heads of terms for a strategic partnership with The John Gore Organisation, ("JGO") a leading developer, producer, distributor and marketer of Broadway theatre worldwide, via JGO's subsidiary; Broadway Channel LLC ("BCL").

The strategic partnership will see the creation of a new joint venture in order to facilitate the VR capture, production and distribution of Broadway theatre content globally. In addition, as part of this co-operation, JGO has provided a £5m investment commitment to the Company to underpin the success of the project and to further align both company's long-term strategic interests.

Under the leadership of 13-time Tony-winning theatre producer and owner John Gore, his family of companies which includes Broadway Across America, Broadway.com, The Broadway Channel, BroadwayBox.com, and Group Sales Box Office ("Broadway"), develops, produces and distributes live theatre content in 45 cities across North America, London's West End, Japan and China. Its Broadway.com platform has featured internationally recognised theatre productions such a Wicked and Disney's The Lion King and provides TV audiences with on-demand access around the world. Broadway has won Tony Awards in every producing category as well as numerous other Drama League, Drama Desk and Olivier Awards. 

 

The first piece of content to be released under the strategic partnership is an exclusive experience featuring Joe Iconis, in which he takes viewers through a tour of the Tony Awards suite at Sofitel New York, before heading to his Tony nominated new musical Be More Chill. The content will be released in companion with the CBS special "At the Tony's" as the theatrical community gears up for Broadway's biggest night. The Be More Chill experience will be the first step in production-driven content. As a leader in capturing and distributing live concerts in VR, MelodyVR in partnership with John Gore and Broadway, is now creating the opportunity for the first Broadway show to be streamed straight to fans homes in full immersive virtual reality.

 

During the year to May 2019 some 14.8 million people attended Broadway shows, including 38 new productions, making it the most attended season in Broadway recorded history (source: The Broadway League]).  Theatre represents a new and exciting vertical for the Company and a further endorsement of the Company's inherent technical expertise. The partnership with Broadway, organisations with a rich established history and proven track record provides for a solid partnership for the creation and distribution of new and exciting VR content appealing to a broad demographic. The growth in attendance for the 2018 – 2019 season topped that of the ten professional New York and New Jersey Sports teams combined (source: The Broadway League) and this initiative will help in making the experience of a theatre production more accessible to everyone.

 

In addition, Mr. John Gore has conditionally agreed to, prior to the expiry of 10 working days from today's date, personally subscribe for 111,111,111 new ordinary shares of 1p each in the Company ("Ordinary Shares") at a price of 4.5p per Ordinary Share, representing an approximate 25.0% premium to the mid-market closing price on 6 June 2019, and also representing approximately 8.5% of the Company's current issued ordinary share capital, to raise gross proceeds of £5.0 million. JGO will also receive an option to subscribe for the equivalent of $10 million of new Ordinary Shares at a price to be determined at the time of exercise which would value the Company's issued equity share capital at approximately £220 million.  The exercise period for this option will expire on 31 December 2019 at which time it will automatically lapse if not exercised. Application will be made for the admission of 111,111,111 new Ordinary Shares to trading on AIM in due course.

 

John Gore, owner and CEO of the John Gore Organization, said, "Every single thing we do at JGO is centred around the goal of serving tantalising content to theatre fans, regardless of their geographical location. Using VR technology is just one more way to deliver Broadway to fans around the globe, especially when the live experience of Broadway and touring Broadway is beyond their reach."

 

Anthony Matchett, Exec. Chairman and CEO of EVR Holdings/Melody VR adds, "Having achieved a series of ground-breaking firsts with the music industry, I'm thrilled to announce our partnership with John Gore, which will see globally recognised theatrical productions made available to consumers worldwide. At the core of MelodyVR, is our vision of connecting fans with unobtainable experiences, in new and immersive ways. Musical theatre is a natural evolution in our journey and I'm pleased that we'll soon be delivering even more amazing content to consumers via our partnership with JGO."

 

 

 

For further information please contact:

 

EVR Holdings plc

Anthony Matchett, Executive Chairman & CEO                                                  Tel: +44 (0) 20 7097 5737

Andy Brown, Chief Financial Officer                                                                         www.evrholdings.com 

 

Investec Bank plc: Nominated Adviser, Financial Adviser                                  Tel: +44 (0) 20 7597 5970

and Corporate Broker

 

Corporate Finance: David Anderson / Junya Iwamoto                                    

 

Corporate Broking: Sara Hale

               

Notes to Editors:

MelodyVR is a wholly owned subsidiary of EVR Holdings plc ('EVR'), a company that is listed on the AIM market of the London Stock Exchange under the ticker EVRH.L.

 

For more information on Melody VR, please visit:

www.melodyvr.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

 

END

 

 

MSCLDLFBKQFXBBE

Close